469 In a separate small 6‐month placebo‐controlled trial, there was a statistical trend for lower relapse rates with fluoxetine compared to placebo. 503 Finally, a post hoc analysis of a large 12‐month placebo‐controlled trial found that response rates to fluoxetine were similar in BDII and MDD. 468 However, it did not report whether fluoxetine was superior to placebo in BDII.
← all excerpts
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
1
—
—